Jefferies lifts Nektar Therapeutics [NKTR] price estimate. Who else is bullish?


Nektar Therapeutics [NASDAQ: NKTR] closed the trading session at $3.58 on 07/15/22. The day’s price range saw the stock hit a low of $3.35, while the highest price level was $3.60. The company report on July 1, 2022 that Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, and is a key member of our Executive Committee. Gil Labrucherie, the company’s current Chief Operating Officer & Chief Financial Officer, will be departing the company to pursue another opportunity at a private biotechnology company.

“Jill brings a deep understanding of financial strategy and operational excellence to her new role,” said Howard Robin, President & CEO at Nektar Therapeutics. “She is a strategic leader that was instrumental in building the Nektar finance organization. In addition to oversight of finance, R&D outsourcing and procurement, Jill has been a vital member of our leadership team executing a wide range of capital market transactions, including debt and equity financings and royalty sales. I am pleased that she will be taking on this broader role for Nektar.”.

The stocks have a year to date performance of -73.50 percent and weekly performance of -6.53 percent. The stock has been moved at -70.85 percent over the last six months. The stock has performed 9.48 percent around the most recent 30 days and changed -41.98 percent over the most recent 3-months.

If compared to the average trading volume of 3.86M shares, NKTR reached to a volume of 15390554 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Nektar Therapeutics [NKTR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $4.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Hold, with their previous recommendation back on May 31, 2022. The new note on the price target was released on April 18, 2022, representing the official price target for Nektar Therapeutics stock. Previously, the target price had yet another drop from $35 to $8, while Mizuho kept a Neutral rating on NKTR stock.

The Average True Range (ATR) for Nektar Therapeutics is set at 0.26, with the Price to Sales ratio for NKTR stock in the period of the last 12 months amounting to 6.16. The Price to Book ratio for the last quarter was 1.09, with the Price to Cash per share for the same quarter was set at 3.76.

NKTR stock trade performance evaluation

Nektar Therapeutics [NKTR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.53. With this latest performance, NKTR shares gained by 9.48% in over the last four-week period, additionally sinking by -70.85% over the last 6 months – not to mention a drop of -78.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKTR stock in for the last two-week period is set at 45.41, with the RSI for the last a single of trading hit 44.53, and the three-weeks RSI is set at 44.56 for Nektar Therapeutics [NKTR]. The present Moving Average for the last 50 days of trading for this stock 3.73, while it was recorded at 3.53 for the last single week of trading, and 9.35 for the last 200 days.

Nektar Therapeutics [NKTR]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Nektar Therapeutics [NKTR] shares currently have an operating margin of -437.76 and a Gross Margin at +65.93. Nektar Therapeutics’s Net Margin is presently recorded at -514.03.

Return on Equity for this stock declined to -59.64, with Return on Assets sitting at -39.45.

Nektar Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.80 and a Current Ratio set at 7.00.

Earnings per share (EPS) analysis for Nektar Therapeutics [NKTR] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -7.30%.

Nektar Therapeutics [NKTR]: Insider Ownership positions

There are presently around $630 million, or 95.60% of NKTR stock, in the hands of institutional investors. The top three institutional holders of NKTR stocks are: INVESCO LTD. with ownership of 37,230,534, which is approximately 0.919% of the company’s market cap and around 0.90% of the total institutional ownership; BLACKROCK INC., holding 26,114,515 shares of the stock with an approximate value of $93.49 million in NKTR stocks shares; and VANGUARD GROUP INC, currently with $69.56 million in NKTR stock with ownership of nearly 4.962% of the company’s market capitalization.

Positions in Nektar Therapeutics stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 131 institutional holders increased their position in Nektar Therapeutics [NASDAQ:NKTR] by around 15,456,837 shares. Additionally, 107 investors decreased positions by around 13,556,372 shares, while 40 investors held positions by with 146,930,104 shares. The mentioned changes placed institutional holdings at 175,943,313 shares, according to the latest SEC report filing. NKTR stock had 39 new institutional investments in for a total of 3,408,628 shares, while 43 institutional investors sold positions of 2,725,285 shares during the same period.